Mürdter, T E <br/><br/>
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.  [electronic resource] 

 -  Clinical pharmacology and therapeutics  May 2011 
 - 708-17 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-6535 
<br/><br/><label>Standard No.: </label>10.1038/clpt.2011.27  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Aryl Hydrocarbon Hydroxylases--blood<br/>Cytochrome P-450 CYP2C19<br/>Cytochrome P-450 CYP2D6--blood<br/>Cytochrome P-450 Enzyme System--blood<br/>Female<br/>Follow-Up Studies<br/>Glucuronosyltransferase--blood<br/>Humans<br/>Middle Aged<br/>Polymorphism, Genetic--genetics<br/>Prospective Studies<br/>Receptors, Estrogen--metabolism<br/>Tamoxifen--blood